AstraZeneca Spins Off Autoimmune Drugs Into New Biotech Company AstraZeneca Spins Off Autoimmune Drugs Into New Biotech Company

AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news